146 related articles for article (PubMed ID: 36290883)
1. Outcomes of Early Transition of Low-Risk Thyroid Cancer Patients from Specialist to Primary Care.
Nguyen P; Azizi-Mehr P; Townsley C; Zahedi A
Curr Oncol; 2022 Oct; 29(10):7672-7679. PubMed ID: 36290883
[TBL] [Abstract][Full Text] [Related]
2. Endocrinologist-Perceived Factors Affecting the Transition of Thyroid Cancer Patients from Specialist to Primary Care Postcancer Treatment in Ontario, Canada.
Janmohamed N; Segal P; Corrado AM; Lofters A; Nguyen P; Townsley C; Zahedi A
Thyroid; 2021 Jun; 31(6):895-901. PubMed ID: 33121388
[No Abstract] [Full Text] [Related]
3. IS IT WORTH SUPPRESSING TSH IN LOW- AND INTERMEDIATE-RISK PAPILLARY THYROID CANCER PATIENTS BEFORE THE FIRST DISEASE ASSESSMENT?
Lamartina L; Montesano T; Falcone R; Biffoni M; Grani G; Maranghi M; Ciotti L; Giacomelli L; Ramundo V; Lomonaco C; Di Gioia CR; Piernatale L; Ronga G; Durante C
Endocr Pract; 2019 Feb; 25(2):165-169. PubMed ID: 30383494
[TBL] [Abstract][Full Text] [Related]
4. Coexistence of thyroglobulin antibodies and thyroid peroxidase antibodies correlates with elevated thyroid-stimulating hormone level and advanced tumor stage of papillary thyroid cancer.
Wu X; Lun Y; Jiang H; Gang Q; Xin S; Duan Z; Zhang J
Endocrine; 2014 Aug; 46(3):554-60. PubMed ID: 24338678
[TBL] [Abstract][Full Text] [Related]
5. Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis.
McLeod DS; Cooper DS; Ladenson PW; Ain KB; Brierley JD; Fein HG; Haugen BR; Jonklaas J; Magner J; Ross DS; Skarulis MC; Steward DL; Maxon HR; Sherman SI;
Thyroid; 2014 Jan; 24(1):35-42. PubMed ID: 23731273
[TBL] [Abstract][Full Text] [Related]
6. Monitoring differentiated thyroid cancer patients with negative serum thyroglobulin. Diagnostic implication of TSH-stimulated antithyroglobulin antibody.
Nam HY; Paeng JC; Chung JK; Kang KW; Cheon GJ; Kim Y; Park DJ; Park YJ; Min HS; Lee DS
Nuklearmedizin; 2014; 53(2):32-8. PubMed ID: 24276613
[TBL] [Abstract][Full Text] [Related]
7. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
[TBL] [Abstract][Full Text] [Related]
8. Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL before the first disease assessment?
Tian T; Huang R; Liu B
Endocrine; 2019 Jul; 65(1):149-154. PubMed ID: 30924085
[TBL] [Abstract][Full Text] [Related]
9. Individualized Follow-Up Strategy for Patients with an Indeterminate Response to Initial Therapy for Papillary Thyroid Carcinoma.
Oh HS; Ahn JH; Song E; Han JM; Kim WG; Kim TY; Kim WB; Shong YK; Jeon MJ
Thyroid; 2019 Feb; 29(2):209-215. PubMed ID: 30384812
[TBL] [Abstract][Full Text] [Related]
10. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
11. Postoperative stimulated thyroglobulin of less than 1 ng/ml as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation.
Rosario PW; Mineiro Filho AF; Prates BS; Silva LC; Calsolari MR
Thyroid; 2012 Nov; 22(11):1140-3. PubMed ID: 23050786
[TBL] [Abstract][Full Text] [Related]
12. Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH.
Pitoia F; Abelleira E; Cross G
Endocrine; 2017 Jan; 55(1):200-208. PubMed ID: 27655291
[TBL] [Abstract][Full Text] [Related]
13. The role of thyroid-stimulating hormone and thyroglobulin antibody in abnormally invasive placenta.
Ozler S; Oztas E; Kebapcilar A; Caglar AT
J Matern Fetal Neonatal Med; 2022 Dec; 35(25):5108-5116. PubMed ID: 33478300
[TBL] [Abstract][Full Text] [Related]
14. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
[TBL] [Abstract][Full Text] [Related]
15. Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma.
Wang PW; Wang ST; Liu RT; Chien WY; Tung SC; Lu YC; Chen HY; Lee CH
J Clin Endocrinol Metab; 1999 Dec; 84(12):4549-53. PubMed ID: 10599717
[TBL] [Abstract][Full Text] [Related]
16. Postoperative Thyroid-Stimulating Hormone Levels Did Not Affect Recurrence after Thyroid Lobectomy in Patients with Papillary Thyroid Cancer.
Lee MC; Kim MJ; Choi HS; Cho SW; Lee GH; Park YJ; Park DJ
Endocrinol Metab (Seoul); 2019 Jun; 34(2):150-157. PubMed ID: 31099202
[TBL] [Abstract][Full Text] [Related]
17. Non-suppressed thyrotropin and elevated thyroglobulin are independent predictors of recurrence in differentiated thyroid carcinoma.
Böhm J; Kosma VM; Eskelinen M; Hollmen S; Niskanen M; Tulla H; Alhava E; Niskanen L
Eur J Endocrinol; 1999 Nov; 141(5):460-7. PubMed ID: 10576761
[TBL] [Abstract][Full Text] [Related]
18. Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients.
Duren M; Siperstein AE; Shen W; Duh QY; Morita E; Clark OH
Surgery; 1999 Jul; 126(1):13-9. PubMed ID: 10418587
[TBL] [Abstract][Full Text] [Related]
19. Detecting Recurrence Following Lobectomy for Thyroid Cancer: Role of Thyroglobulin and Thyroglobulin Antibodies.
Ritter A; Mizrachi A; Bachar G; Vainer I; Shimon I; Hirsch D; Diker-Cohen T; Duskin-Bitan H; Robenshtok E
J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32219303
[TBL] [Abstract][Full Text] [Related]
20. The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels.
Pellegriti G; Scollo C; Regalbuto C; Attard M; Marozzi P; Vermiglio F; Violi MA; Cianci M; Vigneri R; Pezzino V; Squatrito S
Clin Endocrinol (Oxf); 2003 May; 58(5):556-61. PubMed ID: 12699436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
